- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02530658
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Genomes for Kids (G4K)
The development of next generation sequencing (NGS) techniques, including whole genome (WGS), exome (WES) and RNA sequencing has revolutionized the ability of investigators to query the molecular mechanisms underlying tumor formation. Through the Pediatric Cancer Genome Project (PCGP), investigators at St. Jude Children's Research Hospital (SJCRH) have successfully used NGS approaches to evaluate more than 1,000 pediatric cancers ranging from hematologic malignancies to central nervous system (CNS) and non-CNS solid tumors. From these and related studies, it has become clear that genomic approaches can accurately classify tumors into distinct pathologic and prognostic subtypes and detect alterations in cellular pathways that may serve as novel therapeutic targets. Collectively, these studies suggest that by characterizing the genomic make-up of individual tumors, investigators will be able to develop personalized and potentially more effective cancer treatments and/or preventive measures.
This protocol was initially enacted to usher NGS approaches into routine clinical care. During the initial phase of the G4K protocol, 310 participants were recruited and enrolled onto the study. Tumor and/or germline sequencing was completed on all 310 patients, with 253 somatic reports generated (representing 96% of the 263 participants for whom tumor tissue was available and analyzed) and 301 germline reports generated (100% of the 301 participants who agreed to the receipt of germline results). Analyses of the study data are ongoing with plans to prepare initial manuscripts within the next several months. Due to the successful initial execution of the G4K protocol, clinical genomic sequencing of tumor and germline samples is now offered as part of standard clinical care for pediatric oncology patients at St. Jude.
The G4K protocol has now been revised. With the revision, the study team will record, store and analyze germline and tumor genomic information. Through the collection of these data, we will examine how germline mutations in 150 cancer predisposition genes influence clinical presentation, tumor histology, tumor genomic findings, response to therapy and long-term outcomes. The overall goals of this research are to further define the prevalence, spectrum and heritability of germline variants in these genes and to decipher how germline mutations influence the phenotypes of an expanding array of cancer predisposition syndromes. These studies allow us to provide more accurate genetic counseling and management strategies to future children harboring mutations in these genes.
This remains a non-therapeutic study. Investigators anticipate a sample size of approximately 5000 patients who will be recruited over the next 7 years.
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
- To use clinical genomic sequencing to define the prevalence and spectrum of germline mutations in cancer predisposition genes in children with cancer.
- For those identified with germline mutations, to correlate germline genomic information with clinical presentation, tumor genomic findings, treatment response, and outcome.
OTHER PRESPECIFIED OBJECTIVES:
- To generate and analyze data describing patient/parent perceptions of genomic investigations and research at various time points throughout the study.
- To generate and analyze data surrounding the return of genomic sequencing results, examine patient/parent understanding of these results and assess the impact of results on patients and families.
- To determine the feasibility and reliability of performing WES and RNA sequencing on derivatives from formalin-fixed, paraffin-embedded (FFPE) tumor samples alongside the analysis of matched frozen tumor and germline samples.
For participants who give consent, a normal tissue sample will be obtained and used for WGS, WES and RNA sequence analysis. A defined list of 150 genes will be analyzed for reporting using the normal tissue. Once the results of these analyses are available, they will be disclosed to physicians, patients and parents. Mixed measures approaches will be used to assess understanding, acceptance and impact of genomic results on patients and parents. During the course of the study, the investigators anticipate the list of genes to be reported using normal tissue to change due to advances in the literature or other evidence linking additional genes to tumor formation and cancer risk, and new lists may be defined.
To assess provider, patient and family understanding and describe the impacts of genomic testing and return of results, this study will also incorporate administration of surveys and semi-structured interviews. Surveys and interviews are optional, but will be offered to all primary SJCRH providers, as well as all eligible participants and parents, regardless of whether or not they consent to pursue the genomic testing.
A sample of blood or a skin biopsy will be obtained as a source of germline DNA. This sample is necessary as it is the comparator against which tumor samples are evaluated. Skin biopsies may be done on patients who have a diagnosis where peripheral blood is likely to be contaminated by tumor cells.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- St. Jude patients prospectively identified at the time of study activation with a diagnosed solid or liquid tumor (benign or malignant).
- Adequate tissue must be available (e.g. sufficient germline and/or tumor tissue, from which >1 µg DNA and >0.1 µg RNA must be isolated). Patients who have no tumor tissue available may enroll using only germline sample.
Exclusion Criteria:
- Past history of hematopoietic stem cell transplantation (or other condition that would result in hematopoietic cell DNA failing to match host tissue DNA).
- Tumor or germline tissue not meeting the criteria listed above.
- Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
- Participants who are unable to read, write or converse fluently in English will be excluded from Prespecified Objectives 3 and 4.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Participants
St. Jude patients with a diagnosed solid or liquid tumor (benign or malignant) and their biological parents or legally authorized representative. Interventions: Study Introduction Visit, Informed Consent Visit, Informed Consent Follow-Up Visit, Return of Results Conversation, two Return of Results Follow-Up Visits, Tissue Sample (when available), Blood Sample or Skin Biopsy. |
Within 5±3 weeks following arrival at SJCRH, or at the participant/family's convenience, participants will meet with a genetic counselor and clinician, provide information for a family pedigree, undergo a physical and discuss germline testing options.
Study introduction materials will be provided.
Families interested in the G4K study will be referred to the study nurse or other G4K member and an Informed consent visit will be scheduled.
Within 1±3 weeks following the Study Introduction Visit, or at the participant/family's convenience, the research nurse or other study team member will consent the family and collect demographic and medical information.
Participants will complete assessment questionnaires.
Other Names:
Within 2-4 weeks following the Informed Consent Visit, or at the participant/family's convenience, a subset of participants (30-40) will participate in semi-structured interviews.
Other Names:
Participants will complete the assessment questionnaires.
Other Names:
Return of Results Follow-Up Visits will be conducted twice: the first within 8±4 weeks of the Return of Results Conversation, or at the participant/family's convenience, and the second within 32±8 weeks of the Return of Results Conversation or at the participant/family's convenience.
At each visit, participants will complete assessment questionnaires.
Semi-structured interviews with parents and adolescents will be conducted.
Other Names:
For patients who have not previously provided a blood sample, a sample of blood will be obtained as a source of germline DNA.
Other Names:
After consent, for participants with a diagnosis where peripheral blood is likely to be contaminated by tumor cells, skin biopsies may be done as a source of germline DNA.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall success rate
Time Frame: Approximately 3 months after study enrollment
|
Success is defined by the combined successes of (1) quality interpretable genomic data are generated from sequencing tumor and germline tissues, and (2) communicating genomic test results to the primary SJCRH oncologist and the patient and his/her parents. The Binomial proportion of successful performance will be estimated by the sample proportion and the 99% confidence interval based on the normal approximation. Sample size is 400. |
Approximately 3 months after study enrollment
|
Number and type of somatic genetic variants and germline genetic variants
Time Frame: Approximately 3-4 months after the germline sample is obtained
|
WGS, WES and RNA sequence data will be used to identify and characterize somatic genetic variants of pathological significance and germline genetic variants associated with increased cancer risk.
Descriptive statistics, such as counts and proportions of variants associated with increased cancer risk will be computed within each patient and in each disease type.
|
Approximately 3-4 months after the germline sample is obtained
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of parents/participants by perception of genomic testing
Time Frame: At study end (up to 13 months after last participant enrollment)
|
Parent/participant perceptions of genomic investigations and research will be assessed using audiotaped conversations and surveys.
Results will be summarized by descriptive statistics.
|
At study end (up to 13 months after last participant enrollment)
|
Number of participants/parents by level of understanding
Time Frame: At study end (up to 13 months after last participant enrollment)
|
Research participant/parent understanding of genomic results and the impact of results on research participants and their families will be assessed by analysis of audiotaped conversations and survey results.
Results will be summarized by descriptive statistics
|
At study end (up to 13 months after last participant enrollment)
|
Proportion of successful sequences of formalin-fixed, paraffin-embedded (FFPE) samples
Time Frame: Approximately 3 months after enrollment
|
To assess the practicability, proportions of FFPE samples that can be successfully sequenced will be estimated along with a 95% confidence interval.
|
Approximately 3 months after enrollment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kim E. Nichols, MD, St. Jude Children's Research Hospital
Publications and helpful links
General Publications
- Johnson LM, Mandrell BN, Li C, Lu Z, Gattuso J, Harrison LW, Mori M, Ouma AA, Pritchard M, Sharp KMH, Nichols KE. Managing Pandora's Box: Familial Expectations around the Return of (Future) Germline Results. AJOB Empir Bioeth. 2022 Jul-Sep;13(3):152-165. doi: 10.1080/23294515.2022.2063994. Epub 2022 Apr 26.
- Maciaszek JL, Oak N, Chen W, Hamilton KV, McGee RB, Nuccio R, Mostafavi R, Hines-Dowell S, Harrison L, Taylor L, Gerhardt EL, Ouma A, Edmonson MN, Patel A, Nakitandwe J, Pappo AS, Azzato EM, Shurtleff SA, Ellison DW, Downing JR, Hudson MM, Robison LL, Santana V, Newman S, Zhang J, Wang Z, Wu G, Nichols KE, Kesserwan CA. Enrichment of heterozygous germline RECQL4 loss-of-function variants in pediatric osteosarcoma. Cold Spring Harb Mol Case Stud. 2019 Oct 23;5(5):a004218. doi: 10.1101/mcs.a004218. Print 2019 Oct.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- G4K
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid, Liquid, Central Nervous System Tumors
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingAdvanced Solid Tumors Harboring NTRK Fusion | Primary Central Nervous System Tumors Harboring NTRK FusionChina
-
The Hospital for Sick ChildrenSolving Kids' CancerCompletedSolid Tumors | Central Nervous System TumorsCanada, United States
-
University Health Network, TorontoCanadian Cancer Society (CCS); Brain CanadaRecruitingBrain Neoplasms | Liquid BiopsyCanada
-
Turning Point Therapeutics, Inc.RecruitingLymphoma | Locally Advanced Solid Tumors | Metastatic Solid Tumors | Primary CNS TumorsUnited States, Korea, Republic of, Spain, Singapore, Taiwan, Australia, Italy, Canada, France, Denmark, United Kingdom
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Brain and Central Nervous System TumorsCanada, United States
-
The University of Texas Health Science Center at...National Cancer Institute (NCI); Wyeth is now a wholly owned subsidiary of... and other collaboratorsCompletedBrain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
University of PittsburghNational Cancer Institute (NCI)CompletedBrain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Children's Hospital Medical Center, CincinnatiTerminatedSolid Tumors | Brain TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Brain and Central Nervous System TumorsCanada, United States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedBrain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
Clinical Trials on Study Introduction Visit
-
Rush University Medical CenterCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Completed
-
University of RochesterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedSmoking CessationUnited States
-
Wake Forest University Health SciencesInnoTech Precision MedicineNot yet recruitingOropharyngeal Squamous Cell Carcinoma | Human Papillomavirus InfectionUnited States
-
Lawson Health Research InstituteRecruiting
-
Johns Hopkins Bloomberg School of Public HealthMakerere University; The Bloomberg Family Foundation, Inc.; Institute of Epidemiology...CompletedNoncommunicable Diseases | Surveys and QuestionnairesBangladesh, Uganda
-
University of MichiganWinterlight LabsActive, not recruiting
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedObesityUnited Kingdom
-
Siberian Branch of the Russian Academy of Medical...CompletedIschemic Stroke | Hemorrhagic StrokeRussian Federation